Abstract
Over the past decade, as pressures to control health care spending have escalated, the term “cost-effective” has become increasingly commonplace in environments as diverse as the Congress, the business community, managed care organizations, and the pharmaceutical industry. Various factions use this term to serve their own purpose:
-
1
Purchasers of health care use the term to convey a careful assessment of the relative value of different health care services
-
2
Producers of health care technologies and programs use the idea to support marketing claims
-
3
Advocates of special interest groups for particular illnesses and constituencies use the term to garner resource investments
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ariikian S. R., Einarson, T. R., Nguyen, G. K. T., Schubert, F., and the Onychomycosis Study Group, 1994, A multinational pharmacoeconomic analysis of oral therapies for onychomycosis, Br. J. Dermatol 130 (Suppl.43):35-44
Bootman, J. L., Townsend, R. J., and McGhan, W. F.(eds.), 1996, Principles of Pharmacoeconomics. 2nd Ed., Harvey Whitney Books, Cincinnati
Evans, P., 1966, Using health economics to gain a knowledge-based advantage in disease management, presented to DIA, Barcelona, Feb. 1996
Gold, M. R., Siegel, J. E., Russell, L. B., and Weinstein, M. C. (eds.), 1996, Cost Effectiveness in Health and Medicine, Oxford University Press, New York, pp. xvii-xxiii
Hsueh, W., Sun, X., Rioja, L. N., Gonzalez-Crussi, F., 1990, The role of the complement system in shock and tissue injury induced by tumor necrosis factor and endotoxin, J. Immunol 70:309-314
Rajagopalan, R., Anderson, R. T., Sarma, S., Kallal, J., Ritchin, C., Jones, J., Fowler, J. F. Jr., and Sherertz, E. F., 1997, Allergic contact dermatitis: cost effectiveness of early confirmed diagnosis and patch testing, in: Care Management of Skin Diseases: Economic and Life Quality Impact (R. Rajagopalan, R. T. Anderson, and E. F. Sherertz, eds.), Marcel Dekker, New York, pp. 299-316
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rajagopalan, R. (2000). Pharmacoeconomics and Outcomes Research. In: Schwindt, D.A., Maibach, H.I. (eds) Cutaneous Biometrics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1199-1_28
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1199-1_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5437-6
Online ISBN: 978-1-4615-1199-1
eBook Packages: Springer Book Archive